Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes

Stumvoll, 2001, Clinical features of insulin resistance and beta cell dysfunction and the relationship to type 2 diabetes, Clin Lab Med, 21, 31 Bergman, 1987, Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp, J Clin Invest, 79, 790, 10.1172/JCI112886 De Fronzo, 1979, Glucose clamp tecnique: a method for quantifying insulin secretion and resistance, Am J Physiol, E214 Boden, 1991, Effects of fat on insulin-stimulated carbohydrate metabolism in normal men, J Clin Invest, 88, 960, 10.1172/JCI115399 Beysen, 2002, Interaction between specific fatty acids, GLP-1 and insulin secretion in humans, Diabetologia, 45, 1533, 10.1007/s00125-002-0964-9 Hirose, 1996, Defective fatty acid-mediated beta-cell compensation in Zucker diabetic fatty rats. Pathogenic implications for obesity-dependent diabetes, J Biol Chem, 271, 5633, 10.1074/jbc.271.10.5633 Paolisso, 2000, Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients, Atherosclerosis, 121, 10.1016/S0021-9150(99)00352-4 Chan, 2002, Regulatory effects of HMG-CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia, Diabetes, 51, 2377, 10.2337/diabetes.51.8.2377 Staells, 1998, Mechanism of action of fibrates on lipid and lipoprotein metabolism, Circulation, 98, 2088, 10.1161/01.CIR.98.19.2088 Zambón, 1999, Randomized crossover study of gemfibrozil vs lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid reulation, Metabolism, 48, 47, 10.1016/S0026-0495(99)90009-4 Goldberg, 1990, Comparison of the effect of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus, Am J Cardiol, 66, 16B, 10.1016/0002-9149(90)90436-5 Wägner, 2003, Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia, J Clin Endocrinol Metab, 88, 3212, 10.1210/jc.2003-030153 Jeck, 1997, Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM, Diabet Med, 14, 564, 10.1002/(SICI)1096-9136(199707)14:7<564::AID-DIA357>3.0.CO;2-K Winegar, 2001, Effects of fenofibrate on lipid parameters in obese rhesus monkeys, J Lipid Res, 42, 1543, 10.1016/S0022-2275(20)32207-0 Lee, 2002, Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sesitivity in OLEFT rats, Biochem Biophys Res Commun, 296, 293, 10.1016/S0006-291X(02)00822-7 Mussoni, 2000, Effect of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients, Atherosclerosis, 148, 397, 10.1016/S0021-9150(99)00283-X Whitelaw, 2002, Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridemia, Diabetes Obes Metab, 4, 187, 10.1046/j.1463-1326.2002.00199.x Öhrvall, 1995, A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia, Metabolism, 44, 212, 10.1016/0026-0495(95)90267-8 Stewart, 1994, The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hiperlipidaemia, Diabet Med, 12, 250, 10.1111/j.1464-5491.1995.tb00467.x Ogawa, 2000, Bezafibrate reduces blood glucose in type 2 diabetes mellitus, Metabolism, 49, 331, 10.1016/S0026-0495(00)90176-8 Klein, 2002, Recurrent hypoglycaemic episodes in a patient with type 2 diabetes under fibrate therapy, J Diabetes Complications, 16, 246, 10.1016/S1056-8727(01)00186-6